{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:49:47Z","timestamp":1790700587622,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hospital del Mar"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the efficacy and safety of lung low-dose radiation therapy (LD-RT) for pneumonia in patients with coronavirus disease 2019 (COVID-19).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Inclusion criteria comprised patients with COVID-19-related moderate\u2013severe pneumonia warranting hospitalization with supplemental O<jats:sub>2<\/jats:sub> and not candidates for admission to the intensive care unit because of comorbidities or general status. All patients received single lung dose of 0.5\u202fGy. Respiratory and systemic inflammatory parameters were evaluated before irradiation, at 24\u202fh and 1\u00a0week after LD-RT. Primary endpoint was increased in the ratio of arterial oxygen partial pressure (PaO<jats:sub>2<\/jats:sub>) or the pulse oximetry saturation (SpO<jats:sub>2<\/jats:sub>) to fractional inspired oxygen (FiO<jats:sub>2<\/jats:sub>) ratio of at least 20% at 24\u202fh with respect to the preirradiation value.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between June and November 2020, 36\u00a0patients with COVID-19 pneumonia and a\u00a0mean age of 84\u00a0years were enrolled. Seventeen were women and 19 were men and all of them had comorbidities. All patients had bilateral pulmonary infiltrates on chest X\u2011ray. All patients received dexamethasone treatment. Mean SpO<jats:sub>2<\/jats:sub> pretreatment value was 94.28% and the SpO<jats:sub>2<\/jats:sub>\/FiO<jats:sub>2<\/jats:sub> ratio varied from 255\u202fmm Hg to 283\u202fmm Hg at 24\u202fh and to 381\u202fmm Hg at 1\u00a0week, respectively. In those who survived (23\/36, 64%), a\u00a0significant improvement was observed in the percentage of lung involvement in the CT scan at 1\u00a0week after LD-RT. No adverse effects related to radiation treatment have been reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>LD-RT appears to be a\u00a0feasible and safe option in a\u00a0population with COVID-19 bilateral interstitial pneumonia in the presence of significant comorbidities.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-021-01803-3","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T19:02:31Z","timestamp":1625598151000},"page":"1010-1020","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Could pulmonary low-dose radiation therapy be an alternative treatment for patients with COVID-19 pneumonia? Preliminary results of a multicenter SEOR-GICOR nonrandomized prospective trial (IPACOVID trial)"],"prefix":"10.1007","volume":"197","author":[{"given":"M.","family":"Arenas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0500-9202","authenticated-orcid":false,"given":"M.","family":"Algara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"De Febrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"de la Casa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fern\u00e1ndez-Let\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Torres-Royo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Villares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Membrive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"L\u00f3pez-Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Araguas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Quera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rodr\u00edguez-Tom\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"issue":"10229","key":"1803_CR1","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta\u00a0P, McAuley\u00a0DF, Brown\u00a0M, Sanchez\u00a0E, Tattersall\u00a0RS, Manson\u00a0JJ, HLH Across Speciality Collaboration, UK (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033\u20131034. https:\/\/doi.org\/10.1016\/S0140-6736(20)30628-0","journal-title":"Lancet"},{"key":"1803_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/1559325817704760","author":"EJ Calabrese","year":"2017","unstructured":"Calabrese\u00a0EJ, Dhawan\u00a0G, Kapoor\u00a0R (2017) Radiotherapy for pertussis: an historical assessment. Dose Response. https:\/\/doi.org\/10.1177\/1559325817704760","journal-title":"Dose Response"},{"issue":"2","key":"1803_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1667\/rr14080.1","volume":"184","author":"EJ Calabrese","year":"2015","unstructured":"Calabrese\u00a0EJ, Dhawan\u00a0G, Kapoor\u00a0R (2015) The use of X rays in the treatment of bronchial asthma: a historical assessment. Radiat Res 184(2):180\u2013192. https:\/\/doi.org\/10.1667\/rr14080.1","journal-title":"Radiat Res"},{"issue":"4","key":"1803_CR4","first-page":"555","volume":"86","author":"EJ Calabrese","year":"2013","unstructured":"Calabrese\u00a0EJ, Dhawan\u00a0G (2013) How radiotherapy was historically used to treat pneumonia: could it be useful today? Yale J Biol Med 86(4):555\u2013570","journal-title":"Yale J Biol Med"},{"issue":"11","key":"1803_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00066-012-0170-8","volume":"188","author":"M Arenas","year":"2012","unstructured":"Arenas\u00a0M, Sabater\u00a0S, Hern\u00e1ndez\u00a0V et al (2012) Anti-inflammatory effects of low-dose radiotherapy. Indications, dose, and radiobiological mechanisms involved. Strahlenther Onkol 188(11):975\u2013981. https:\/\/doi.org\/10.1007\/s00066-012-0170-8","journal-title":"Strahlenther Onkol"},{"key":"1803_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fonc.2012.00120","volume":"2","author":"F R\u00f6del","year":"2012","unstructured":"R\u00f6del\u00a0F, Frey\u00a0B, Manda\u00a0K et al (2012) Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x\u2011irradiation. Front Oncol 2:120. https:\/\/doi.org\/10.3389\/fonc.2012.00120","journal-title":"Front Oncol"},{"issue":"10","key":"1803_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3109\/09553002.2012.689464","volume":"88","author":"B L\u00f6dermann","year":"2012","unstructured":"L\u00f6dermann\u00a0B, Wunderlich\u00a0R, Frey\u00a0S et al (2012) Low dose ionising radiation leads to a\u00a0NF-\u03baB dependent decreased secretion of active IL-1\u03b2 by activated macrophages with a\u00a0discontinuous dose-dependency. Int J Radiat Biol 88(10):727\u2013734","journal-title":"Int J Radiat Biol"},{"issue":"2","key":"1803_CR8","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.rpor.2020.02.004","volume":"25","author":"L Torres Royo","year":"2020","unstructured":"Torres Royo\u00a0L, Antelo Redondo\u00a0G, \u00c1rquezPianetta\u00a0M, Arenas Prat\u00a0M (2020) Low-Dose radiation therapy for benign pathologies. Rep Pract Oncol Radiother 25(2):250\u2013254. https:\/\/doi.org\/10.1016\/j.rpor.2020.02.004","journal-title":"Rep Pract Oncol Radiother"},{"issue":"3","key":"1803_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.radonc.2007.10.032","volume":"86","author":"M Arenas","year":"2008","unstructured":"Arenas\u00a0M, Gil\u00a0F, Gironella\u00a0M et al (2008) Time course of anti-inflammatory effect of low-dose radiotherapy: correlation with TGF-beta(1) expression. Radiother Oncol 86(3):399\u2013406. https:\/\/doi.org\/10.1016\/j.radonc.2007.10.032","journal-title":"Radiother Oncol"},{"key":"1803_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4103\/atm.ATM_433_20","volume":"15","author":"BN Pandey","year":"2020","unstructured":"Pandey\u00a0BN (2020) Low-dose radiation therapy for coronavirus disease-2019 pneumonia: is it time to look beyond apprehensions? Ann Thorac Med 15:199\u2013207","journal-title":"Ann Thorac Med"},{"key":"1803_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ctro.2020.06.005","volume":"24","author":"M Algara","year":"2020","unstructured":"Algara\u00a0M, Arenas\u00a0M, Marin\u00a0J et al (2020) Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: a proposal for a\u00a0multi-centric prospective trial. Clin Transl Radiat Oncol 24:29\u201333. https:\/\/doi.org\/10.1016\/j.ctro.2020.06.005","journal-title":"Clin Transl Radiat Oncol"},{"issue":"7","key":"1803_CR12","doi-asserted-by":"publisher","first-page":"102567","DOI":"10.1016\/j.autrev.2020.102567","volume":"19","author":"Y Jamilloux","year":"2020","unstructured":"Jamilloux\u00a0Y, Henry\u00a0T, Belot\u00a0A et al (2020) Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev 19(7):102567. https:\/\/doi.org\/10.1016\/j.autrev.2020.102567","journal-title":"Autoimmun Rev"},{"key":"1803_CR13","doi-asserted-by":"publisher","first-page":"m2980","DOI":"10.1136\/bmj.m2980","volume":"370","author":"RA Siemieniuk","year":"2020","unstructured":"Siemieniuk\u00a0RA, Bartoszko\u00a0JJ, Ge\u00a0L et al (2020) Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 370:m2980. https:\/\/doi.org\/10.1136\/bmj.m2980","journal-title":"BMJ"},{"issue":"2","key":"1803_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.23812\/CONTI-E","volume":"34","author":"P Conti","year":"2020","unstructured":"Conti\u00a0P, Ronconi\u00a0G, Caraffa\u00a0A et al (2020) Induction of pro-inflammatory cytokines (IL\u20111 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J\u00a0Biol Regul Homeost Agents 34(2):327\u2013331. https:\/\/doi.org\/10.23812\/CONTI-E","journal-title":"J Biol Regul Homeost Agents"},{"key":"1803_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.03.012","author":"HK Siddiqi","year":"2020","unstructured":"Siddiqi\u00a0HK, Mehra\u00a0MR (2020) COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J\u00a0Heart Lung Transplant. https:\/\/doi.org\/10.1016\/j.healun.2020.03.012","journal-title":"J Heart Lung Transplant"},{"key":"1803_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","author":"P Horby","year":"2020","unstructured":"RECOVERY Collaborative Group, Horby\u00a0P, Lim\u00a0WS, Emberson\u00a0JR et al (2020) Dexamethasone in hospitalized patients with Covid-19\u2014preliminary report. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2021436","journal-title":"N Engl J Med"},{"key":"1803_CR17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","author":"JH Beigel","year":"2020","unstructured":"Beigel\u00a0JH, Tomashek\u00a0KM, Dodd\u00a0LE, ACTT\u20111 Study Group Members et al (2020) Remdesivir for the treatment of Covid-19\u2014final report. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"issue":"9","key":"1803_CR18","doi-asserted-by":"publisher","first-page":"e1003293","DOI":"10.1371\/journal.pmed.1003293","volume":"17","author":"S Juul","year":"2020","unstructured":"Juul\u00a0S, Nielsen\u00a0EE, Feinberg\u00a0J et al (2020) Interventions for treatment of COVID-19: a living systematic review with meta-analyses and trial sequential analyses (the LIVING project). PLoS Med 17(9):e1003293. https:\/\/doi.org\/10.1371\/journal.pmed.1003293","journal-title":"PLoS Med"},{"key":"1803_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ijid.2020.06.107","volume":"98","author":"M Sun","year":"2020","unstructured":"Sun\u00a0M, Xu\u00a0Y, He\u00a0H et al (2020) A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. Int J Infect Dis 98:334\u2013346. https:\/\/doi.org\/10.1016\/j.ijid.2020.06.107","journal-title":"Int J Infect Dis"},{"key":"1803_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.radonc.2020.05.002","volume":"147","author":"G Dhawan","year":"2020","unstructured":"Dhawan\u00a0G, Kapoor\u00a0R, Dhawan\u00a0R et al (2020) Low dose radiation therapy as a\u00a0potential life saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS). Radiother Oncol 147:212\u2013216. https:\/\/doi.org\/10.1016\/j.radonc.2020.05.002","journal-title":"Radiother Oncol"},{"key":"1803_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ctro.2020.04.006","volume":"23","author":"PC Lara","year":"2020","unstructured":"Lara\u00a0PC, Burgos\u00a0J, Macias\u00a0D (2020) Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a\u00a0cost-effective anti-inflammatory treatment. Clin Transl Radiat Oncol 23:27\u201329. https:\/\/doi.org\/10.1016\/j.ctro.2020.04.006","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"1803_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1667\/RADE-20-00211.1","volume":"194","author":"PG Prasanna","year":"2020","unstructured":"Prasanna\u00a0PG, Woloschak\u00a0GE, DiCarlo\u00a0AL et al (2020) Low-dose radiation therapy (LDRT) for COVID-19: benefits or risks? Radiat Res 194(5):452\u2013464. https:\/\/doi.org\/10.1667\/RADE-20-00211.1","journal-title":"Radiat Res"},{"issue":"5","key":"1803_CR23","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ijrobp.2020.07.026","volume":"108","author":"A Ameri","year":"2020","unstructured":"Ameri\u00a0A, Rahnama\u00a0N, Bozorgmehr\u00a0R et al (2020) Low-dose whole-lung irradiation for COVID-19 pneumonia: short course results. Int J Radiat Oncol Biol Phys 108(5):1134\u20131139. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.07.026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1803_CR24","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1002\/cncr.33130","volume":"126","author":"CB Hess","year":"2020","unstructured":"Hess\u00a0CB, Buchwald\u00a0ZS, Stokes\u00a0W et al (2020) Low-dose whole-lung radiation for COVID-19 pneumonia: planned day 7 interim analysis of a\u00a0registered clinical trial. Cancer 126:5109\u20135113. https:\/\/doi.org\/10.1002\/cncr.33130","journal-title":"Cancer"},{"key":"1803_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.12.011","author":"CB Hess","year":"2021","unstructured":"Hess\u00a0CB, Nasti\u00a0TH, Dhere\u00a0V et al (2021) Immunomodulatory low-dose whole-lung radiation for patients with COVID-19-related pneumonia. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.12.011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1803_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00066-020-01743-4","volume":"197","author":"E Moreno-Olmedo","year":"2021","unstructured":"Moreno-Olmedo\u00a0E, Su\u00e1rez-Gironzini\u00a0V, P\u00e9rez\u00a0M, Filigheddu\u00a0T, M\u00ednguez\u00a0C, Sanjuan-Sanjuan\u00a0A, Gonz\u00e1lez\u00a0JA, Rivas\u00a0D, Gorospe\u00a0L, Larrea\u00a0L, L\u00f3pez\u00a0E (2021) COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): a\u00a0single institution report of two cases. Strahlenther Onkol 197(5):429\u2013437. https:\/\/doi.org\/10.1007\/s00066-020-01743-4","journal-title":"Strahlenther Onkol"},{"issue":"12","key":"1803_CR27","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1007\/s00066-020-01675-z","volume":"196","author":"R Del Castillo","year":"2020","unstructured":"Del Castillo\u00a0R, Martinez\u00a0D, Sarria\u00a0GJ et al (2020) Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review. Strahlenther Onkol 196(12):1086\u20131093. https:\/\/doi.org\/10.1007\/s00066-020-01675-z","journal-title":"Strahlenther Onkol"},{"key":"1803_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.11.049","author":"N Sanmamed","year":"2020","unstructured":"Sanmamed\u00a0N, Alcantara\u00a0P, Cerezo\u00a0E et al (2020) Low dose radiotherapy in the management of covid19 pneumonia (LOWRAD-Cov19). Preliminary report. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.11.049","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1803_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.02.054","author":"A Papachristofilou","year":"2021","unstructured":"Papachristofilou\u00a0A, Finazzi\u00a0T, Blum\u00a0A, Zehnder\u00a0T, Zellweger\u00a0N, Lustenberger\u00a0J, Bauer\u00a0T, Dott\u00a0C, Avcu\u00a0Y, Kohler\u00a0G, Zimmermann\u00a0F, Pargger\u00a0H, Siegemund\u00a0M (2021) Low-dose radiation therapy for severe COVID-19 pneumonia: a randomized double-blind study. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.02.054","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1803_CR30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.radonc.2005.06.034","volume":"76","author":"JT Jansen","year":"2005","unstructured":"Jansen\u00a0JT, Broerse\u00a0JJ, Zoetelief\u00a0J, Klein\u00a0C, Seegenschmiedt\u00a0HM (2005) Estimation of the carcinogenic risk of radiotherapy of benign diseases from shoulder to heel. Radiother Oncol 76(3):270\u2013277. https:\/\/doi.org\/10.1016\/j.radonc.2005.06.034","journal-title":"Radiother Oncol"},{"key":"1803_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejmp.2017.01.014","volume":"42","author":"M Mazonakis","year":"2017","unstructured":"Mazonakis\u00a0M, Damilakis\u00a0J (2017) Cancer risk after radiotherapy for benign diseases. Phys Med 42:285\u2013291","journal-title":"Phys Med"},{"issue":"1056","key":"1803_CR32","doi-asserted-by":"publisher","first-page":"20150405","DOI":"10.1259\/bjr.20150405","volume":"88","author":"SR McKeown","year":"2015","unstructured":"McKeown\u00a0SR, Hatfield\u00a0P, Prestwich\u00a0RJ, Shaffer\u00a0RE, Taylor\u00a0RE (2015) Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation. Br J Radiol 88(1056):20150405. https:\/\/doi.org\/10.1259\/bjr.20150405","journal-title":"Br J Radiol"},{"issue":"2","key":"1803_CR33","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/09553002.2021","volume":"97","author":"GV Arruda","year":"2021","unstructured":"Arruda\u00a0GV, Weber\u00a0RRDS, Bruno\u00a0AC, Pavoni\u00a0JF (2021) The risk of induced cancer and ischemic heart disease following low dose lung irradiation for COVID-19: estimation based on a\u00a0virtual case. Int J Radiat Biol 97(2):120\u2013125. https:\/\/doi.org\/10.1080\/09553002.2021","journal-title":"Int J Radiat Biol"},{"key":"1803_CR34","doi-asserted-by":"publisher","first-page":"110532","DOI":"10.1016\/j.biopha.2020.110532","volume":"130","author":"Q Fan","year":"2020","unstructured":"Fan\u00a0Q, Zhang\u00a0B, Ma\u00a0J, Zhang\u00a0S (2020) Safety profile of the antiviral drug remdesivir: an update. Biomed Pharmacother 130:110532. https:\/\/doi.org\/10.1016\/j.biopha.2020.110532","journal-title":"Biomed Pharmacother"},{"key":"1803_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104955","author":"SW Choi","year":"2020","unstructured":"Choi\u00a0SW, Shin\u00a0JS, Park\u00a0SJ et al (2020) Antiviral activity and safety of remdesivir against SARS-CoV\u20112 infection in human pluripotent stem cell-derived cardiomyocytes. Antiviral Res. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104955","journal-title":"Antiviral Res"},{"issue":"9","key":"1803_CR36","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/jcph.1693","volume":"60","author":"S Khiali","year":"2020","unstructured":"Khiali\u00a0S, Khani\u00a0E, Entezari-Maleki\u00a0T (2020) A comprehensive review of tocilizumab in COVID-19 acute respiratory distress syndrome. J\u00a0Clin Pharmacol 60(9):1131\u20131146. https:\/\/doi.org\/10.1002\/jcph.1693","journal-title":"J Clin Pharmacol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01803-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-021-01803-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01803-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T12:03:38Z","timestamp":1635941018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-021-01803-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1803"],"URL":"https:\/\/doi.org\/10.1007\/s00066-021-01803-3","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Funding information section was missing from this article and should have read \u201cOpen Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.\u201d","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Arenas, M.\u00a0Algara, G.\u00a0De Febrer, C.\u00a0Rubio, X.\u00a0Sanz, M.A.\u00a0de la Casa, C.\u00a0Vasco, J.\u00a0Mar\u00edn, P.\u00a0Fern\u00e1ndez-Let\u00f3n, J.\u00a0Villar, L.\u00a0Torres-Royo, P.\u00a0Villares, I.\u00a0Membrive, J.\u00a0Acosta, M.\u00a0L\u00f3pez-Cano, P.\u00a0Araguas, J.\u00a0Quera, F.\u00a0Rodr\u00edguez-Tom\u00e1s and A.\u00a0Montero declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}